After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.
The team integrated tumor barcoding, genome editing, and ultra-deep barcode sequencing to interrogate pairwise combinations of tumor suppressor alterations.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
Farsight Genome Systems is touting the rapid scalability of its analytic pipeline as it seeks to make its technology "future-proof" for clinical genomics labs.
Chugai, a member of the Roche Group, has already filed for regulatory approval of FoundationOne CDx with Japan's Ministry of Health, Labor, and Welfare.
With multiple independent biomarkers, and potential combinations that may require even more subtyping, diagnostics to guide immunotherapy appears to be getting more complicated.
A decade after their team at WashU sequenced the first tumor-normal genome pair, Mardis and Wilson are bringing cancer genomics to the clinic at Nationwide Children's Hospital.
In a study published in PLOS One last month, the researchers compared results from the BGISEQ-500 and the Illumina HiSeq X Ten for tumor and germline samples from three patients.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.
